Refine Group (”Refine”, ”koncernen” eller ”bolaget”) publicerade den 23 augusti 2024 bolagets delårs...
Redeye provides its comment on Mendus’ Q2 2024 report.
I en utmanande omgivning tar New Wave marknadsandelar och ökar nu marknadssatsningarna.
Redeye provides a research update following the Q2 report published by Initiator Pharma earlier toda...
Lyckegård Group AB (”Lyckegård” eller ”Bolaget”) består fr.
CoinShares International (CS) posted a strong adjusted EBITDA in Q224 of £26.
Solteq is set to start showing clearly improved profitability figures, with the toughest actions now...
Redeye sees a solid report with Q2 numbers mainly in-line with our expectations.
Redeye states the report was weak, and it is apparent that InfraCom struggles with its Connect acqui...
Redeye comments on Heliospectra’s Q2 results, noting that sales were weaker than expected due to sho...
Redeye provides an initial comment on the Q2 2024 report from Kancera, which showed lower operating ...
Redeye states the report was in line with preannounced figures and slightly ahead on sales with a 25...
Redeye comments on I-Tech’s Q2 figures that were stronger than our expectations in all regards.
Redeye provides a research update following the Q2 report recently published by Coegin Pharma.
Redeye’s long-term view of Dignitana is, to a degree, intact, even if the sales progression has been...
Redeye provides an update following WntResearch’s Q2 report.
Redeye updates on Better Collective following its Q2-results which were in line with our expectation...
Redeye leaves a research update following Klaria Pharma’s recently published Q2 2024 report.
Sales +4%, adj. EBITA -4% vs. cons, +5% org. sales Cons to lower '24e adj.
We lower '24e revenue by 21%, but lift '26e by 18% 2nd IPU design win secured, pipeline continues to...
